Foghorn Therapeutics share price logo

Foghorn Therapeutics

NASDAQ: FHTX

$2.02

+0.02

(+0.75%)

Live

as on

Foghorn Therapeutics Stock Performance

as on October 24, 2026 at 6:28 am IST

  • Day's Low

    Day's High

    $1.90
    $2.03
    downward going graph

    5.94%

    Downside

    0.50%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $1.79
    $7.61
    downward going graph

    11.39%

    Downside

    276.73%

    Upside

    downward going graph

Foghorn Therapeutics share price movements today

Previous Close
$2.01
Open
$1.95
Volume
359.9K
Market Cap
$121.1M
Day's Low - High
$1.90 - $2.03
52 Week Low - High
$1.79 - $7.61

Foghorn Therapeutics Historical Returns

1 Month Return
-48.06 %
3 Month Return
-60.36 %
1 Year Return
-48.46 %
3 Year Return
-34.95 %
5 Year Return
-84.17 %

Foghorn Therapeutics Stock Fundamentals & Key Indicators

Check Foghorn Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$121.1M

EPS (TTM)

-0.99

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-2.06

Industry PE ratio

-3.14

PEG Ratio

-0.12

EBITDA

-62.5M

Revenue (TTM)

36.7M

Profit Margin

42.73%

Return On Equity TTM

72.64%

Foghorn Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Foghorn Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Foghorn Therapeutics image
Foghorn Therapeutics
Buy$121.1M-84.17%-2.0642.73%0.00%
Moderna image
Moderna
Neutral$98.1B-37.95%-30.80-12.57%0.00%
BeOne Medicines image
BeOne Medicines
StrongBuy$44.0BNA27.4787.82%0.00%
Vertex Pharmaceuticals image
Vertex Pharmaceuticals
StrongBuy$132.9B191.61%30.2886.04%0.00%
Regeneron image
Regeneron
Buy$83.1B43.11%19.2484.86%0.46%

Stock Returns calculator for Foghorn Therapeutics Stock including INR - Dollar returns

The Foghorn Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Foghorn Therapeutics investment value today

Current value as on today

₹56,020

Returns

-₹43,980

(-43.98%)

Returns from Foghorn Therapeutics Stock

-₹48,205 (-48.21%)

Dollar Impact

₹4,225 (+4.23%)

Analyst Recommendation on Foghorn Therapeutics Stock

Based on 7 analysts

BUY

28.57%

Buy

71.43%

Hold

0.00%

Sell

Based on 7 analysts, 71.42857142857143% of analysts recommend a 'BUY' rating for Foghorn Therapeutics. Average target price of $4.17

Foghorn Therapeutics Share Price Target

Get share price movements and forecasts by analysts on Foghorn Therapeutics.

What analysts predicted

51.56%UPSIDE

Target Price

$4.17

Current Price

$2.02

Analyzed by

7 Analysts

High

$5

Target

$4.17

Low

$2

Foghorn Therapeutics target price $4.17, a slight upside of 51.56% compared to current price of $2.02. According to 7 analysts rating.

Indian Investors' Interest in Foghorn Therapeutics Stock

Search interest for Foghorn Therapeutics Stock has increased by 285% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:285% versus previous 30 day period

Foghorn Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
5
6
7
2
5
7
8
9
3
16
Gross Profit
5
6
7
2
5
6
-11
8
3
16
Operating Income
-28
-26
-23
-24
-22
-21
-18
-19
-21
-8
EBITDA
-24
-23
-18
-18
-18
-17
-14
-20
-19
-6
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-25
-22
-19
-19
-18
-17
-15
-21
-19
-7
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-25
-22
-19
-19
-18
-17
-15
-21
-19
-7
Net Profit Margin
100.00%
100.00%
100.00%
100.00%
100.00%
88.09%
-145.33%
91.33%
92.72%
100.00%

Foghorn Therapeutics Annual Profit & Loss

All numbers in Millions USD

Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
0
1
19
34
22
30
Gross Profit
0
-1
-57
1
19
34
22
27
Operating Income
-26
-51
-68
-100
-117
-107
-102
-82
EBITDA
-25
-49
-67
-96
-105
-90
-97
-70
Interest Expense
0
0
0
1
-
-
-
-
Depreciation
0
0
1
3
3
3
3
3
Income Before Tax
-26
-51
-68
-101
-108
-94
-86
-74
Income Tax Expense
0
-
-
-
-
4
-
-
Net Income
-26
-51
-68
-101
-108
-98
-86
-74
Net Profit Margin
0.00%
0.00%
-13322.09%
100.00%
100.00%
100.00%
100.00%
89.22%

Foghorn Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-25
-22
-19
-19
-18
-17
-15
-21
-19
-7
Operating Cash Flow
-29
-25
-21
-24
-23
-21
-18
-22
-25
-18
Investing Cash Flow
27
-17
-61
22
29
33
35
13
-17
-2
Financing Cash Flow
1
103
1
0
0
0
0
0
49
-49
Change in Cash
-1
59
-81
-2
5
12
16
-8
6
-71

Foghorn Therapeutics Annual Cash Flow

All numbers in Millions USD

Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-26
-51
-68
-101
-108
-98
-86
-74
Operating Cash Flow
-22
-46
-31
-50
193
-118
-100
-86
Investing Cash Flow
-1
0
-108
36
-244
144
-29
112
Financing Cash Flow
51
23
217
22
1
1
105
1
Change in Cash
27
-23
77
8
-48
28
-24
26

Global Institutional Holdings in Foghorn Therapeutics

Check out the Institutions with significant holdings in Foghorn Therapeutics.

Funds
Holdings
Noubar Afeyan
21.34%
James E. Flynn
7.40%
Fidelity Mt. Vernon Street Trust
4.50%
Vanguard
3.03%
iShares
2.81%
See all

Foghorn Therapeutics News & Key Events

  • img

    Today's Timeline - 02 October

    Fri, 03:47 PM

    -

    H.C. Wainwright cuts Foghorn's price target to $5, keeps Buy rating amid disappointing clinical outcomes.

    Fri, 04:20 PM

    -

    Guggenheim lowers Foghorn's price target to $5, maintains Buy rating despite halted collaboration with Eli Lilly.

    Fri, 04:45 PM

    -

    Wedbush downgrades Foghorn to Neutral with a price target cut to $2 after Lilly collaboration ends.

  • img

    Today's Timeline - 02 October

    Fri, 07:20 PM

    -

    Foghorn Therapeutics lays off 40% workforce after Eli Lilly ends cancer drug partnership, shares drop 16%.

Insights on Foghorn Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 3.26M → 16.07M (in $), with an average increase of 79.7% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, FHTX stock has moved up by 8.6%

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 3 quarters, -21.66M → -7.19M (in $), with an average increase of 92.7% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Moderna, Inc. Common Stock has given 157.7% return, outperforming this stock by 192.7%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 671.9% return, outperforming this stock by 720.4%

About Foghorn Therapeutics

Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines. Their focus is on addressing genetically determined vulnerabilities within the chromatin regulatory system. The company employs its exclusive "Gene Traffic Control" platform to pinpoint, validate, and strategize drug development for specific targets within this complex system. Its pipeline includes FHD-286, a small-molecule agent engineered to halt the enzymatic activity of BRG1 and BRM. This compound is being developed to treat metastatic uveal melanoma, as well as acute myeloid leukemia and myelodysplastic syndrome that have either recurred or are resistant to previous therapies. Another key candidate, FHD-609, is a small-molecule protein degrader designed to target BRD9, intended for patients diagnosed with synovial sarcoma. Beyond these, Foghorn is also further developing a selective enzymatic inhibitor and a protein degrader, both designed to modulate BRM. Additionally, they are working on ARID1B selective modulators, with potential applications in treating ovarian, endometrial, colorectal, bladder, and gastric cancers. The company has forged strategic alliances, including a research collaboration and licensing agreement with Merck Sharp & Dohme Corp. aimed at unearthing and creating novel oncology therapies focused on a transcription factor target. They also collaborate with Loxo Oncology to devise new cancer treatments. Foghorn Therapeutics Inc. was established in 2015 and maintains its headquarters in Cambridge, Massachusetts.
OrganisationFoghorn Therapeutics
Headquarters99 Coolidge Avenue, Watertown, MA, 02472, US
IndustryBiotechnology
CEOAdrian H. Gottschalk

Key Management of Foghorn Therapeutics

Name

Title

Mr. Adrian H. B. Gottschalk

President, CEO & Director

Dr. Alfonso Quintas Cardama M.D.

Chief Medical Officer

Dr. Gerald R. Crabtree M.d.

Founder & Member of Scientific Advisory Board

Ms. Karin Hellsvik

Chief of Staff to the CEO, VP, Head of Corporate Affairs, Investor Relations & Operations

Mr. Saurabh Sewak Ph.D.

Vice President of Corporate Development

Dr. Douglas G. Cole M.D.

Founder & Independent Chairman of the Board

Dr. Steven F. Bellon Ph.D.

Chief Scientific Officer

Mr. Ryan D. Maynard

Chief Financial Officer

Mr. Michael J. LaCascia J.D.

Chief Legal Officer

Mr. Carlos Costa

Chief People Officer

FAQs

What is Foghorn Therapeutics share price today?

Foghorn Therapeutics share price today is $2.02 as on . Foghorn Therapeutics share today touched a day high of $2.03 and a low of $1.90.

What is the 52 week high and 52 week low for Foghorn Therapeutics share?

Foghorn Therapeutics share touched a 52 week high of $7.61 on and a 52 week low of $1.79 on . Foghorn Therapeutics stock price today i.e. is trending at $2.02,which is 73.46% down from its 52 week high and 12.85% up from its 52 week low.

What is Foghorn Therapeutics's market capitalisation today?

Foghorn Therapeutics market capitalisation is $0.00T as on .

How to invest in Foghorn Therapeutics Stock (FHTX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Foghorn Therapeutics on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Foghorn Therapeutics Stock (FHTX) from India?

Indian investors can start investing in Foghorn Therapeutics (FHTX) shares with as little as ₹94.94000244140625 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹949.40 in Foghorn Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on Foghorn Therapeutics share’s latest price of $2.02 as on October 24, 2026 at 12:58 am IST, you will get 4.9505 shares of Foghorn Therapeutics. Learn more about fractional shares .

What are the returns that Foghorn Therapeutics has given to Indian investors in the last 5 years?

Foghorn Therapeutics stock has given -84.17% share price returns and 26.35% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?